WAP
CLSD

Wealthcare Advisory Partners’s Clearside Biomedical CLSD Stock Holding History

Wealthcare Advisory Partners’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-53
Closed -$2K – 783
2021
Q1 		$2K Buy
+53
New +$2.66K ﹤0.01% 1847

Other funds holding CLSD

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Wealthcare Advisory Partners's CLSD Position: Q2 2021 in Review

Wealthcare Advisory Partners sold out of Clearside Biomedical (CLSD) in Q2 2021, closing a stake of 53 shares — an estimated $2K sold.

Wealthcare Advisory Partners first reported a position in CLSD in Q1 2021 and held it in 1 quarter. The position peaked at $2K in Q1 2021. 52 funds tracked by Wall St. Rank hold CLSD as of Q2 2021.

  • Wealthcare Advisory Partners reported no remaining Clearside Biomedical position as of Q2 2021 after selling out during the quarter.
  • Wealthcare Advisory Partners sold 53 Clearside Biomedical shares in Q2 2021, an estimated $2K.
  • Wealthcare Advisory Partners first reported a position in Clearside Biomedical in Q1 2021 and held it in 1 quarter.
  • Wealthcare Advisory Partners's Clearside Biomedical position peaked at $2K in Q1 2021.
  • 52 funds tracked by Wall St. Rank held Clearside Biomedical as of Q2 2021.

Based on Wealthcare Advisory Partners's 13F filing for Q2 2021, filed 16 Aug 2021.